Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders
Huge Study Finds Constellation of Health Benefits for Ozempic Beyond Weight Loss
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss.
GLP-1 drugs like Ozempic may have health benefits, but they come with risks
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, are among the most common adverse effects.
GLP-1 weight-loss drugs may cut risk of dementia and other conditions
GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and dementia.
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
Major study of weight-loss jabs shows slew of benefits but also risks
The risk of heart attack and stroke declines, but gastrointestinal problems and joint inflammation increase: New research has shed more light on the pros and cons of weight-loss jabs.
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
Pharmacists in warning over weight-loss jab sales
Weight-loss jabs, known as GLP-1 receptor agonists, work by reducing food cravings. The NPA has previously urged patients to ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Medical News Today5d
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Popular Weight Loss Drugs Could Affect Your Behavior: Scientists Conduct Genetic Investigation
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Daily1h
Novel Obesity Drug Induces Weight Loss Up to 22% with No Safety Concerns in clinical trial
In a phase 1b/2a trial subcutaneous amycretin demonstrated a safety profile similar to other incretin-based drugs . Adults ...
phillyvoice.com4d
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
Hosted on MSN5d
What Is It Like Losing Weight on a GLP-1? 10 People Share Their Stories
Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...
Demand for loose skin surgery rises with GLP-1 weight loss meds
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...